



Tanja N Fehm

Kontakt

Tanja N Fehm

Publikationen (21)

Fehm T, Müller V, Banys-Paluchowski M, Fasching P, Friedl T, Hartkopf A, Huober J, Loehberg C, Rack B, Riethdorf S, Schneeweiss A, Wallwiener D, Meier-Stiegen F, Krawczyk N, Jaeger B, Reinhardt F, Hoffmann O, Müller L, Wimberger P, Ruckhäberle E, Blohmer J, Cieslik J, Franken A, Niederacher D, Neubauer H, Pantel K, Janni W, DETECT study group. Efficacy of Lapatinib in Patients with HER2-Negative Metastatic Breast Cancer and HER2-Positive Circulating Tumor Cells-The DETECT III Clinical Trial. *Clin Chem* 2024; 70:307-318.

Fasching P, Decker T, Hartkopf A, Nusch A, Heinrich B, Kurbacher C, Fuchs R, Tesch H, Krabisch P, Huober J, Kümmel S, Brucker S, Janni W, Schneeweiss A, Schuler M, Fehm T, Luftner D, Quiring C, Voges C, Kreuzeder J, Reinisch M. Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer. *Eur J Cancer* 2023; 198:113480.

Thill M, Kolberg-Liedtke C, Albert U, Banys-Paluchowski M, Bauerfeind I, Blohmer J, Budach W, Dall P, Ditsch N, Fallenberg E, Fasching P, Fehm T, Friedrich M, Gerber B, Gluz O, Harbeck N, Hartkopf A, Heil J, Huober J, Jackisch C, Kreipe H, Krug D, Kühn T, Kümmel S, Loibl S, Luftner D, Lux M, Maass N, Mundhenke C, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn H, Solbach C, Solomayer E, Stickeler E, Thomssen C, Untch M, Witzel I, Wöckel A, Müller V, Wuerstlein R, Janni W, Park-Simon T. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2023. *Breast Care (Basel)* 2023; 18:306-315.

Park-Simon T, Müller V, Jackisch C, Albert U, Banys-Paluchowski M, Bauerfeind I, Blohmer J, Budach W, Dall P, Ditsch N, Fallenberg E, Fasching P, Fehm T, Friedrich M, Gerber B, Gluz O, Harbeck N, Hartkopf A, Heil J, Huober J, Kolberg-Liedtke C, Kreipe H, Krug D, Kühn T, Kümmel S, Loibl S, Luftner D, Lux M, Maass N, Mundhenke C, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn H, Solbach C, Solomayer E, Stickeler E, Thomssen C, Untch M, Witzel I, Wöckel A, Wuerstlein R, Janni W, Thill M. Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2023. *Breast Care (Basel)* 2023; 18:289-305.

Huebner H, Ruebner M, Kurbacher C, Hadji P, Hartkopf A, Lux M, Huober J, Uhrig S, Taran F, Overkamp F, Tesch H, Häberle L, Luftner D, Wallwiener M, Müller V, Beckmann M, Hein A, Belleville E, Untch M, Janni W, Fehm T, Kolberg H, Wallwiener D, Brucker S, Schneeweiss A, Ettl J, Fasching P, Michel L. Return of individual genomic research results within the PRAEGNANT multicenter registry study. *Breast Cancer Res Treat* 2022

Ditsch N, Wöckel A, Untch M, Jackisch C, Albert U, Banys-Paluchowski M, Bauerfeind I, Blohmer J, Budach W, Dall P, Fallenberg E, Fasching P, Fehm T, Friedrich M, Gerber B, Gluz O, Harbeck N, Heil J, Huober J, Kreipe H, Krug D, Kühn T, Kümmel S, Kolberg-Liedtke C, Loibl S, Luftner D, Lux M, Maass N, Mundhenke C, Nitz U, Park-Simon T, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn H, Solbach C, Solomayer E, Stickeler E, Thomssen C, Witzel I, Müller V, Janni W, Thill M. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022. *Breast Care (Basel)* 2022; 17:403-420.

Huebner H, Tesch H, Brucker S, Blohmer J, Fehm T, Heinrich G, Rezai M, Beckmann M, Fasching P, Janni W, Schneeweiss A, Nabieva N, Jückstock J, Häberle L, Müller V, Schrader I, Lorenz R, Forstbauer H, Fink V, Schochter F, Bekes I, Mahner S, Rack B. MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients. *Cancers (Basel)* 2022; 14

Schneeweiss A, Lux M, Müller V, Nabieva N, Overkamp F, Tesch H, Laakmann E, Taran F, Seitz J, Thomssen C, Untch M, Wimberger P, Wuerstlein R, Volz B, Wallwiener D, Wallwiener M, Klein E, Kurbacher C, Ettl J, Luftner D, Beckmann M, Belleville E, Fasching P, Fehm T, Geberth M, Häberle L, Hadji P, Hartkopf A, Hielscher C, Huober J, Ruckhäberle E, Janni W, Kolberg H, Brucker S. Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany". *Breast* 2021; 55:138-139.

Huebner H, Beckmann M, Belleville E, Ruebner M, Untch M, Fasching P, Janni W, Fehm T, Kolberg H, Wallwiener D, Brucker S, Schneeweiss A, Müller V, Wallwiener M, Kurbacher C, Kuesters G, Hartkopf A, Lux M, Huober J, Volz B, Taran F, Overkamp F, Tesch H, Häberle L, Luftner D, Ettl J. HERGULIN (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany. *BMC cancer* 2020; 20:1091.

Tesch H, Luftner D, Schneeweiss A, Lux M, Fehm T, Overkamp F, Welslau M, Schulmeyer C, Kolberg H, Fasching P, Huober J, Thill M, Hartkopf A, Schütz F, Belleville E, Ettl J, Wöckel A, Müller V, Janni W. Update Breast Cancer 2020 Part 4 - Advanced Breast Cancer. *Geburtshilfe Frauenheilkd* 2020; 80:1115-1122.

Huober J, Schütz F, Luftner D, Fehm T, Tesch H, Overkamp F, Welslau M, Schulmeyer C, Kolberg H, Fasching P, Thill M, Belleville E, Ettl J, Janni W, Lux M, Müller V, Hartkopf A, Schneeweiss A, Wöckel A. Update Breast Cancer 2020 Part 3 - Early Breast Cancer. *Geburtshilfe Frauenheilkd* 2020; 80:1105-1114.

De Gregorio A, Schneeweiss A, Tesch H, Mahner S, Brucker S, Blohmer J, Fehm T, Heinrich G, Lato K, Beckmann M, Rack B, Andergassen U, Bekes I, Fink V, Häberle L, Fasching P, Müller V, Schrader I, Lorenz R, Forstbauer H, Friedl T, Bauer E, De Gregorio N, Deniz M, Janni W. Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer - results from the randomized phase III SUCCESS-A trial. *Breast Cancer Res* 2020; 22:111.

Michel L, Hielscher C, Mundhenke C, Kurbacher C, Wuerstlein R, Untch M, Overkamp F, Huober J, Janni W, Taran F, Lux M, Wallwiener D, Brucker S, Schneeweiss A, Wimberger P, Huebner H, Hartkopf A, Fasching P, Kolberg H, Hadji P, Tesch H, Häberle L, Ettl J, Luftner D, Wallwiener M, Müller V, Beckmann M, Belleville E, Volz B, Fehm T. Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab. *Cancers (Basel)* 2020; 12

Schneeweiss A, Lux M, Müller V, Nabieva N, Overkamp F, Tesch H, Laakmann E, Taran F, Seitz J, Thomssen C, Untch M, Wimberger P, Wuerstlein R, Volz B, Wallwiener D, Wallwiener M, Klein E, Kurbacher C, Ettl J, Luftner D, Beckmann M, Belleville E, Fasching P, Fehm T, Geberth M, Häberle L, Hadji P, Hartkopf A, Hielscher C, Huober J, Ruckhäberle E, Janni W, Kolberg H, Brucker S. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. *Breast* 2020; 54:88-95.

Luftner D, Fehm T, Tesch H, Overkamp F, Welslau M, Pöschke P, Kolberg H, Fasching P, Huober J, Thill M, Schütz F, Belleville E, Ettl J, Janni W, Wöckel A, Müller V, Hartkopf A, Schneeweiss A, Lux M. Update Breast Cancer 2020 Part 2 - Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics. *Geburtshilfe Frauenheilkd* 2020; 80:391-398.

Schneeweiss A, Luftner D, Fehm T, Tesch H, Overkamp F, Welslau M, Pöschke P, Kolberg H, Fasching P, Thill M, Huober J, Belleville E, Ettl J, Janni W, Lux M, Wöckel A, Müller V, Hartkopf A, Schütz F. Update Breast Cancer 2020 Part 1 - Early Breast Cancer: Consolidation of Knowledge About Known Therapies. *Geburtshilfe Frauenheilkd* 2020; 80:277-287.

Kolberg H, Wallwiener M, Overkamp F, Tesch H, Ettl J, Luftner D, Müller V, Schütz F, Fasching P, Taran F, Hartkopf A, Janni W, Schneeweiss A, Fehm T, Wöckel A, Huober J, Pontones C, Titzmann A, Belleville E, Lux M, Brucker S. Update Breast Cancer 2019 Part 3 - Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel. *Geburtshilfe Frauenheilkd* 2019; 79:470-482.

Lux M, Wimberger P, Hielscher C, Geberth M, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Fasching P, Janni W, Fehm T, Wallwiener D, Schneeweiss A, Belleville E, Beckmann M, Müller V, Nabieva N, Hartkopf A, Huober J, Volz B, Taran F, Overkamp F, Kolberg H, Hadji P, Tesch H, Häberle L, Ettl J, Luftner D, Wallwiener M, Brucker S. Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry. *Cancers (Basel)* 2018; 11

Lux M, Wallwiener M, Müller V, Beckmann M, Belleville E, Fehm T, Wallwiener D, Brucker S, Schneeweiss A, Luftner D, Huober J, Ettl J, Janni W, Hartkopf A, Nabieva N, Taran F, Overkamp F, Kolberg H, Hadji P, Tesch H, Fasching P. Update Breast Cancer 2017 - Implementation of Novel Therapies. *Geburtshilfe Frauenheilkd* 2017; 77:1281-1290.

Hartkopf A, Wimberger P, Hielscher C, Geberth M, Fersis N, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Fasching P, Janni W, Fehm T, Wallwiener D, Brucker S, Belleville E, Beckmann M, Müller V, Huober J, Volz B, Nabieva N, Taran F, Schwitulla J, Overkamp F, Kolberg H, Hadji P, Tesch H, Häberle L, Ettl J, Lux M, Luftner D, Wallwiener M, Schneeweiss A. Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry. *Breast* 2017; 37:42-51.

Solomayer E, Huober J, Wallwiener D, Neubauer H, Vogel U, Krämer B, Bachmann R, Pergola-Becker G, Becker S, Fehm T. Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients. *Breast cancer research and treatment* 2006; 98:179-84.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen Rorschacher Strasse 95 CH-9007 St.Gallen T: +41 71 494 11 11 support.forschung@kssg.ch